Beyond Air (XAIR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
5 May, 2026Executive summary
Special Meeting scheduled for June 18, 2026, to vote on a reverse stock split and potential adjournment if more votes are needed.
The reverse stock split aims to increase the share price to meet Nasdaq's $1.00 minimum bid price requirement and avoid delisting.
The Board has discretion to set the split ratio between 1-for-2 and 1-for-20 at any time within one year of the meeting.
If delisted from Nasdaq, shares may trade OTC, which could reduce liquidity and access to capital.
The Board recommends voting in favor of both proposals.
Voting matters and shareholder proposals
Proposal 1: Approve an amendment to effect a reverse stock split at a ratio of 1-for-2 to 1-for-20, at the Board's discretion.
Proposal 2: Approve adjournment of the meeting if more time is needed to solicit votes for Proposal 1.
Both proposals are considered routine matters, allowing brokers to vote uninstructed shares.
Approval of Proposal 1 requires a majority of shares present and entitled to vote.
Board of directors and corporate governance
The Board has full discretion to determine if and when to implement the reverse split within one year of approval.
No other matters are expected to be presented at the meeting.
Latest events from Beyond Air
- Vote on a reverse stock split to maintain Nasdaq listing and authorize meeting adjournment if needed.XAIR
Proxy filing24 Apr 2026 - Q3 revenue up 105% YoY, net loss narrowed, and global expansion continues.XAIR
Q3 202613 Apr 2026 - Patented tankless NO technology drives rapid growth and pipeline expansion in respiratory and oncology markets.XAIR
Corporate presentation23 Mar 2026 - Revenue grew to $1.2M, guidance lowered, and regulatory delays impacted margins.XAIR
Q4 20243 Feb 2026 - Offering up to 7.86M shares for resale, with proceeds from warrant exercises for corporate use.XAIR
Registration Filing30 Jan 2026 - Second-generation nitric oxide device targets major U.S. and global market share growth.XAIR
2nd Annual Lytham Partners Healthcare Investor Summit15 Jan 2026 - LungFit PH revolutionizes NO therapy with on-demand generation, global reach, and expanding clinical pipeline.XAIR
Corporate presentation15 Jan 2026 - Hospital client base grew 60% and revenue quadrupled, with losses narrowed and cash runway extended.XAIR
Q2 202515 Jan 2026 - CE Mark approval, new partnerships, and next-gen product set stage for global growth in 2025-27.XAIR
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026